CLEARMIND BIOMEDICAL

Clearmind Biomedical Group develops proprietary micro-invasive surgical technologies for the treatment of intracerebral hemorrhage (ICH) and brain hemorrhage (hemorrhagic stroke). The company focuses on simplifying and streamlining operating room procedures while improving patient outcomes. Hemorrhagic stroke remains the deadliest form of stroke with mortality rates of 36–60%, and fewer than 20% of patients achieve functional independence three months post-event. Traditional brain surgery approaches produce poor outcomes despite annual treatment of over 4.6 million patients globally. Clearmind's platform addresses this clinical need through proprietary micro-invasive technology designed to reduce procedural complexity, operative time, and patient morbidity. The company collaborates closely with neurosurgeons to inform product design and ensure alignment with clinical requirements. All products emphasize quality and efficiency in neurosurgical care, with particular emphasis on improving access to ICH treatment for all patient populations.